Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
Contrast-Induced Nephropathy
About this trial
This is an interventional prevention trial for Contrast-Induced Nephropathy focused on measuring Coronary Angiography, Side Effects, Contrast-Induced Nephropathy, Prevention
Eligibility Criteria
Inclusion Criteria:
- adult patients
- candidate of elective coronary angiography or angioplasty
- at least moderate risk for contrast induced nephropathy
Exclusion Criteria:
- unstable angina or myocardial infarction, cardiac arrhythmia, seizures, acute renal failure, end-stage renal disease
- unstable serum creatinine
- unstable hemodynamic
- intravascular administration of contrast material in the past month
- using theophylline or N-acetylcysteine in the past month,
- known hypersensitivity to theophylline or N-acetylcysteine
Sites / Locations
- Chamran HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
N-acetylcysteine
Theophylline
Theophylline plus N-acetylcysteine
Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.